Filing Details
- Accession Number:
- 0001209191-18-028324
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-05-07 16:28:03
- Reporting Period:
- 2018-05-07
- Accepted Time:
- 2018-05-07 16:28:03
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1557746 | Aclaris Therapeutics Inc. | ACRS | Pharmaceutical Preparations (2834) | 460571712 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1654450 | Frank Ruffo | C/O Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-05-07 | 1,250 | $18.22 | 156,865 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.
- This transaction was executed in multiple trades at prices ranging from $18.22 to $18.28, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.